Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision v3.6.5 was added and v3.6.4 removed in the page history, indicating a new version of the record history rather than changes to study details.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe revision label was updated from v3.6.3 to v3.6.4, reflecting a new build of the page. No study content or functionality is affected.SummaryDifference0.1%

- Check47 days agoChange DetectedThe history now includes a new entry for Revision: v3.6.3 and removes the previous v3.6.2 entry, reflecting an updated software release in the page's history.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page footer revision tag was updated from v3.6.0 to v3.6.2, indicating a newer version of the study record history page; this is a metadata update with no changes to the displayed study data.SummaryDifference0.1%

- Check69 days agoChange DetectedRecruitment status updated to 'No longer looking for participants', indicating enrollment is closed. The history now shows Revision: v3.6.0 and removes the prior Revision: v3.5.5 entry.SummaryDifference0.2%

- Check76 days agoChange DetectedA new revision entry v3.5.5 was added to the study record history, representing an updated version of the record. The previous revision v3.5.4 remains part of the history as the prior version.SummaryDifference0.1%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.